FDA approval of Provention Bio’s teplizumab could bring the first disease-modifying therapy to the type 1 diabetes space

shutterstock_171515726
If approved by the FDA, teplizumab will be the first disease-modifying therapy for T1D and could be brought to the market by the mid-to-end of 2021. Credit: Image Point Fr.